肺胞蛋白症の英語

日本バイオアッセイ研究センターの長期がん原性試験結果では、雌雄のラットに104週間、0.01、0.03、0.1mg/m3濃度でITO研削粉をばく露させた結果、最低濃度の0.01mg/m3においてラットで肺胞蛋白症、肺胞上皮の過形成、肺胞壁の線維化、マウスでも肺胞蛋白症の発生増加が見られた。例文帳に追加

In the carcinogenicity study by Japan Bioassay Research Center, male and female rats were exposed to 0.01,0.03 and 0.1mg/m3 ITO grinding dusts for 104 weeks.Growth and proliferation of pulmonary alveolar proteinosis, alveolar epithelial hyperplasia and fibrosis of alveolar walls were observed in the lungs of rats of both sexes at the minimum concentration of 0.01mg/m3 . - 厚生労働省

新たなプロテアーゼ阻害剤、慢性閉塞性肺疾患・免疫不全症候群・肺胞蛋白症・循環器疾患の根治的治療薬及び治療法を提供すること。例文帳に追加

To provide a novel protease inhibitor and permanent curative medicines and treating methods for chronic obstructive pulmonary disease, immunodeficiency syndrome, pulmonary alveolar proteinosis, and circulatory disorders. - 特許庁

新たなプロテアーゼ阻害剤、慢性閉塞性肺疾患・免疫不全症候群・肺胞蛋白症・循環器疾患の根治的治療薬及び治療法を提供すること。例文帳に追加

To provide a new protease inhibitor, and to provide a definite-curative remedy and a therapeutic method for chronic obstructive pulmonary diseases, immunodeficiency syndrome, pulmonary alveolar proteinosis and circulatory diseases. - 特許庁

レドックス活性蛋白質を除く，及び慢性閉塞性肺疾患又は免疫不全症候群の予防又は治療剤，並びに、ＩＬ−１８またはこれをコードする遺伝子から選択される少なくとも一種以上を含むことを特徴とする、慢性閉塞性肺疾患・肺胞蛋白症・循環器疾患の予防又は治療剤。例文帳に追加

The preventive or therapeutic agent is used for chronic obstructive pulmonary disease or immunodeficiency syndrome, and the preventive or therapeutic agent for chronic obstructive pulmonary disease, alveolar proteinosis or circulatory disease is contains at least one kind selected from IL-18 excluding redox-active protein and a gene encoding the same. - 特許庁